Autopsy report · NCT03784599

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“insufficient effectiveness”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 2 years 5 months before it stopped.
28 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: The Netherlands Cancer Institute
Sponsor type: University, hospital or other
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Trastuzumab emtansine; Osimertinib
Participants: 28
Sites: 5
Countries: Netherlands

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.